Semaglutide During Pregnancy: Safety & Clinical Considerations

Last reviewed: May 20, 2026

Last updated: May 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide is contraindicated during pregnancy and should be discontinued before conception. Current clinical guidelines and FDA labeling recommend women of childbearing age avoid semaglutide use due to insufficient safety data and animal reproductive toxicity studies raising concern for fetal risk.

Pregnancy planning requires a shift in weight management strategy. Understanding your individual metabolic predispositions—including genetic factors influencing insulin sensitivity and appetite regulation—can help you and your provider design a safe, sustainable approach during reproductive years.

Why Semaglutide Is Not Recommended During Pregnancy

GLP-1 receptor agonists, including semaglutide, lack adequate human pregnancy safety data. Animal studies in rats and rabbits demonstrated fetal toxicity at doses comparable to therapeutic human exposure, prompting the FDA to classify semaglutide as Pregnancy Category C (later updated to category X in some contexts).

The mechanism of GLP-1 receptor signaling extends beyond glucose regulation to include developmental pathways in the fetus. Without long-term human pregnancy studies, the full scope of potential effects on fetal organogenesis, placental function, and postnatal development remains unknown.

Clinical Evidence and Regulatory Guidance on GLP-1 Use in Reproductive Years

Multiple professional societies—including ACOG (American College of Obstetricians and Gynecologists) and the Endocrine Society—recommend discontinuing GLP-1 receptor agonists before attempting conception. The timing of discontinuation varies; most guidance suggests stopping at least one menstrual cycle before trying to conceive.

Clinical Factor	Key Evidence or Recommendation
FDA Pregnancy Category	Category X or C depending on formulation; insufficient human data
Animal Reproductive Studies	Fetal toxicity observed in rats/rabbits at therapeutic doses
Recommended Discontinuation Timing	At least 1 menstrual cycle before conception attempts
Mechanism of Concern	GLP-1 receptors expressed in fetal tissues; unknown developmental impact
Lactation	Unknown if semaglutide passes into breast milk; not recommended during nursing

Planning Pregnancy: Biomarkers and Genetic Insights for Metabolic Health

Before conception, understanding your metabolic baseline—including fasting glucose, insulin resistance markers, and inflammatory biomarkers—provides a clearer picture of your weight management needs. These metrics inform what strategies will work best during pregnancy without pharmacotherapy.

Genetic predispositions in metabolic pathways (FTO rs9939609, MC4R rs17782313) influence how your body regulates hunger and energy expenditure. Knowing these patterns can help you and your provider design nutrition and lifestyle interventions suited to your biology during pregnancy planning and throughout pregnancy.

Safe Weight Management Alternatives During Pregnancy and Postpartum

Evidence-based alternatives for pregnancy include structured nutrition counseling, regular moderate-intensity exercise (as cleared by your OB), behavioral weight management, and psychological support. These approaches carry no reproductive toxicity risk and support healthy maternal and fetal outcomes.

Postpartum represents a critical window: some women may resume GLP-1 therapy after delivery if not breastfeeding, but this decision requires careful provider evaluation. Lactating mothers should avoid semaglutide and other GLP-1 agents until safety data in human milk is established.

How to Discuss GLP-1 Use and Pregnancy Planning With Your Provider

If you are taking semaglutide and planning pregnancy, schedule a dedicated pre-conception visit. Inform your provider about your current dose, duration of use, and weight management goals so they can create a transition plan that maintains metabolic health while discontinuing the medication safely.

Bring your metabolic and genetic data to this conversation if available. Understanding your individual risk factors for gestational diabetes, hypertension, and postpartum weight retention helps your provider recommend evidence-based lifestyle and dietary strategies tailored to your biology.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your individual predispositions in GLP-1 and metabolic pathways (GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, MC4R rs17782313) before conception. These insights can support a more informed conversation with your provider about which weight management approaches may align best with your biology during pregnancy planning.

The genetic test reveals predispositions in peptide and metabolic genetic pathways, not exact medication response or pregnancy outcomes. This information should be interpreted with a qualified healthcare provider who understands your full medical history, reproductive goals, and individual risk factors.

Understanding your metabolic genetic signature before conception can help you and your provider design a personalized nutrition and lifestyle strategy for pregnancy that addresses your individual hunger regulation, insulin sensitivity, and weight management patterns without pharmacotherapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.